DICER1 D1709N

CI-VAR-00000432Explore in graph →CIViC 2051

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Ovarian Sertoli-Leydig Cell Tumor2
DICER1 D1709N	(diagnostic)	Diagnostic	B	Does Not Support Positive	4	accepted	EID5534 In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC) PMID 26428316 · Conlon et al., 2015 · Open in CIViC	civic
DICER1 D1709N	(predisposing)	Predisposing	B	Supports Predisposition	3	accepted	EID5886 DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N… (full text at CIViC) PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Glandular Pattern Ovarian Yolk Sac Tumor1unmapped disease
DICER1 D1709N	(oncogenic)	Oncogenic	C	Supports Oncogenicity	1	accepted	EID5899 DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). There was one Yolk sac tumor that had a somatic mutation in D1709N. PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC	civic